A new venture fund will invest in reproductive medicine. Here’s what’s worth watching in the field

The field of fertility medicine is booming right now. Women are waiting longer and longer to have children. Same-sex couples looking to start families are increasingly turning to in vitro fertilization. And investors are pouring money into startups pitching egg freezing and genetic testing and other services to young women.

There are few observers more qualified to weigh in on this business than Dr. David Sable. Sable previously spent years as an IVF doctor and now he invests in biotech on Wall Street, as a portfolio manager for the firm Special Situations.

Sable got on the phone with STAT to talk about how he sees the future of IVF.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In